Twist Bioscience (TWST) Barclays 28th Annual Global Healthcare Conference summary

Business strategy and AI integration

• Resegmentation into SynBio and protein solutions aligns with AI-driven drug discovery trends, enabling faster and more scalable workflows for customers using computational antibody design.

• DNA synthesis and protein solutions grew 27% year-over-year in Q1, with therapeutic drug discovery revenue reaching $111 million and growing over 25%.

• AI enables customers to generate thousands of antibody sequences, which are rapidly synthesized, characterized, and returned with data in as little as 15 days.

• AI-driven workflows reduce drug discovery timelines from six weeks to two, allowing for multiple rounds of optimization and contributing to business momentum.

Product and service expansion

• The company aims to offer a comprehensive menu of DNA, protein, and data services, catering to both traditional and AI-driven drug discovery customers.

• The Invenra acquisition adds a high-throughput platform for bispecific antibody discovery, overcoming previous industry bottlenecks in purification and scalability.

• Invenra's engineered linker technology reduces immunogenicity risk and is already in clinical use.

• The company maintains flexibility to support customer-preferred workflows, even if not leveraging proprietary high-throughput advantages.

Capacity, project selection, and commercial approach

• Maintains a customer-centric approach, aiming never to turn down projects if commercially viable, while ensuring fair value for services.

• DNA synthesis capacity is robust, with 3 million gene capacity per year and significant headroom for growth.

• Data characterization demand is ramping quickly, growing over 200% last year, prompting proactive capacity expansion.